A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
Completed
Pfizer
Phase 3
2006-12-01
The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with
placebo for treating moderate to severe chronic pain over a 12 week period.
Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients
Terminated
Pfizer
Phase 4
2010-04-01
This study will evaluate whether crushed EMBEDA capsules induce clinical opiate withdrawal
signs and symptoms in opioid-dependent patients with chronic non-cancer pain who are
stabilized on EMBEDA.
The purpose of the research study is to find out if opioid dependent chronic pain patients
who are judged by their physician to be eligible to change their current opioid medicine and
to participate in this study can be successfully adjusted to a stable dose of EMBEDA
(morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's
risk for prescription opioid abuse, misuse and diversion.
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Completed
Pfizer
Phase 1
2011-02-01
The primary purpose of this study is to determine the abuse potential of EMBEDA compared to
controlled release morphine when crushed and taken orally by non-dependent recreational
opioid users; secondary purposes include to determine the abuse potential of crushed EMBEDA
relative to placebo and and to compare the pharmacokinetics and safety of crushed EMBEDA with
crushed controlled-release morphine and crushed placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
